TD Cowen Raises Danaher (DHR) Price Target to $270
Key Points
- TD Cowen reiterated a Buy rating on Danaher Corporation on October 22, 2026, while bumping its price target up to $270 from $255.
- TD Cowen's $270 price target implies 15.75% upside from Danaher Corporation's ($DHR) current $233.27 share price.
- Capital International Investors held 15,504,420 shares valued at about $3.56 billion after growing its position by 1,489,759 shares.
- Danaher trades with a trailing twelve month revenue of $25.11 billion and a forward price-to-earnings ratio of 25.1.
Get Danaher text alerts
We text you when insiders, Congress, analysts or big funds move on $DHR.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Danaher Corporation alert may contain errors. Disclosures
On October 22, 2026, TD Cowen maintained its Buy rating on Danaher Corporation $DHR and raised its price target from $255.00 to $270.00. The research note reflects the firm's ongoing positive view on the healthcare company's market position.
DHR
Danaher Corporation
TD Cowen's Call on Danaher
In its October 22 update, TD Cowen kept a Buy rating in place while pushing its target higher by $15. The adjustment points to a more optimistic view on the stock compared to its prior $255 target.
Other Institutional Activity in Danaher
Capital International Investors grew its holdings by 1,489,759 shares, ending with 15,504,420 shares worth about $3,558,962,060 during the period ending June 30, 2026.
Danaher Corporation Stock Up 4.0%
Danaher shares closed at $229.54 on October 22, 2026, and recently traded around $233.27, putting the stock up about 1.6% since that close. The recent price sits well above its 50-day moving average of $215.12 and its 200-day average of $201.26. The stock trades below its 52-week high of $242.80.
$DHR price target
Danaher Corporation daily closes and this analyst's $270 target. Not advice.
Recent Earnings
Danaher generated trailing-twelve-month revenue of $25,106,992,960 and earnings of $6.04 per share. The company reported a net profit margin of 15.9% and a return on equity of 7.6%.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
-
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 5 target cuts.
-
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.
Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Danaher pays an annual dividend rate of $1.60 per share, giving it a dividend yield of 0.71% with a payout ratio of 25.7%.
Insider Buying and Selling at Danaher Corporation
Alan G Spoon, Director, sold 1,358 shares at an average price of $174.67 for a total value of $237,207 on May 1, 2026. Later, Chief Executive Officer Rainer M Blair disposed of 58,255 shares for a total value of $12,736,095 on August 21, 2026.
Analysts Set New Price Targets
On October 22, 2026, Barclays maintained its Overweight rating and raised its target from $255.00 to $260.00. On the same day, JP Morgan maintained its Overweight rating and lifted its target from $250.00 to $270.00. Stifel also maintained a Buy rating while hiking its target from $220.00 to $260.00, and Baird maintained an Outperform rating with a target moved from $246.00 to $254.00. Wall Street currently holds a consensus strong buy rating on the stock with a mean price target of $247.18 across 22 analyst opinions.
About Danaher
Danaher Corporation builds professional, medical, research, and industrial products and services. The firm operates across biotechnology, life sciences, and diagnostics segments, serving customers globally from its headquarters in Washington, DC.
Bottom Line
Investors will want to track how Danaher performs against analyst expectations as the next reporting cycle approaches. Price targets across Wall Street continue to shift as firms reassess the healthcare sector.
Related Filing Alerts
Source: TD Cowen's rating change on $DHR (Oct 22, 2026). Written by software, not financial advice. How we make alerts